MC2 Biotek, a clinical stage emerging specialty pharmaceutical company focusing on dermatology and ophthalmology, today announced that it has changed its name to MC2 Therapeutics.
Jesper J. Lange, President of MC2 Therapeutics says:
“We are excited about the progress in our drug development programs. It has strengthened our efforts to build a new specialty pharmaceutical company based on new topical drugs and OTC products designed to provide patients a superior experience. We have chosen to strengthen our corporate identity in order to provide all stakeholders clarity on our strategic focus.”
BACK
